New Drug First Major Breakthrough for Alzheimer’s in the Past Decade

This drug combined with antibody therapies could prevent or even cure the neurodegenerative disorder. 


Amyloid beta plaques are gooey globs that clump together, stick to neurons inside the brain and kill them off, outright. The slow but steady accumulation of these plaques leads to Alzheimer’s disease. Tau protein tangles aid them by cutting off the brain’s supply lines, as the plaques march across white and gray matter, taking out the memory and cognitive ability, and wreaking havoc on the patient and their family. No treatment can halt this invasion once it occurs. But now, a small trial for an experimental drug is lending patients and loved ones hope.

This drug inhibits the production of these plaques, according to a small study. Scientists at Merck Research Laboratories have announced the drug Verubecestat. In a small, phase I trial it “switched off” the production of the amyloid proteins that form these plaques. This in turn slowed the progression of the disease.  

University College London neuroscientist John Hardy, who played a role in amyloid plaque’s implication in Alzheimer’s, warned in an interview with The Guardian, that it is too soon to start breaking out the champagne. The results are from this phase I clinical trial including a mere 32 participants.  

Even so, team leader for the Merck project, Matthew Kennedy, told Scientific American that this was the first effective BACE1 inhibitor that also maintained a good safety profile. Two follow-up trials, currently ongoing, including together 3,500 participants, should give us more insight into its efficacy and safety profile, long-term. Each will last 18 months or longer. One includes 1,500 prodromal patients, where the disease is in its seminal stages, and the other with 2,000 patients who each have mild-to-moderate disease. The first trial ends in 2019, while the second will show results next year.

Enzyme snipping amyloid precursor proteins.

If effective, Verubecestat will be the first breakthrough treatment for Alzheimer’s in a decade. For the phase I trial, each participant took the medication in pill form, once a day for a week. A control group who did not have Alzheimer’s, took the drug daily for two weeks. No side effects were reported.

Enzymes in the body produce proteins. This drug is designed to inhibit the enzyme BACE1. By doing so, the production of amyloid proteins is halted. BACE1 is thought to slice amyloid precursor proteins (APP) to bits, which go on and form globules that gunk up the gray and white matter. These two trials should also help solve a longstanding debate among the Alzheimer’s research community. There is a split over whether amyloid beta protein or tau tangles are the primary driver of the disease. Most believe amyloid protein is.

These findings arrived at an auspicious time. President Barack Obama recently dubbed November national Alzheimer’s awareness month. The administration has set the lofty goal of preventing or curing Alzheimer’s by 2025. Several treatments in the works may reap results. This BACE1 inhibitor is among the most promising.

On another front, in a study published in the journal Nature, antibody therapies were shown to break up existing amyloid plaque buildup. In that study, the drug Aducanumab was used. Researchers speculate that this could be combined with a BACE1 inhibitor like Verubecestat in order to recoup areas of the brain already affected, while at the same time, blocking the production of amyloid protein. Though dead neurons cannot be revived, living ones can be salvaged.

To learn more about Alzheimer’s treatment click here: 

LinkedIn meets Tinder in this mindful networking app

Swipe right to make the connections that could change your career.

Getty Images
Swipe right. Match. Meet over coffee or set up a call.

No, we aren't talking about Tinder. Introducing Shapr, a free app that helps people with synergistic professional goals and skill sets easily meet and collaborate.

Keep reading Show less

The dos and don’ts of helping a drug-addicted person recover

How you talk to people with drug addiction might save their life.

  • Addiction is a learning disorder; it's not a sign that someone is a bad person.
  • Tough love doesn't help drug-addicted people. Research shows that the best way to get people help is through compassion, empathy and support. Approach them as an equal human being deserving of respect.
  • As a first step to recovery, Maia Szalavitz recommends the family or friends of people with addiction get them a complete psychiatric evaluation by somebody who is not affiliated with any treatment organization. Unfortunately, warns Szalavitz, some people will try to make a profit off of an addicted person without informing them of their full options.
Keep reading Show less

10 science photos that made history and changed minds

These photos of scientific heroes and accomplishments inspire awe and curiosity.

Surprising Science
  • Science has given humanity an incalculable boost over the recent centuries, changing our lives in ways both awe-inspiring and humbling.
  • Fortunately, photography, a scientific feat in and of itself, has recorded some of the most important events, people and discoveries in science, allowing us unprecedented insight and expanding our view of the world.
  • Here are some of the most important scientific photos of history:
Keep reading Show less

In a first for humankind, China successfully sprouts a seed on the Moon

China's Chang'e 4 biosphere experiment marks a first for humankind.

Image source: CNSA
Surprising Science
  • China's Chang'e 4 lunar lander touched down on the far side of the moon on January 3.
  • In addition to a lunar rover, the lander carried a biosphere experiment that contains five sets of plants and some insects.
  • The experiment is designed to test how astronauts might someday grow plants in space to sustain long-term settlements.
Keep reading Show less